240 related articles for article (PubMed ID: 25893270)
1. d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS.
Cianci A; Panella M; Fichera M; Falduzzi C; Bartolo M; Caruso S
Gynecol Endocrinol; 2015 Jun; 31(6):483-6. PubMed ID: 25893270
[TBL] [Abstract][Full Text] [Related]
2. Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women.
Artini PG; Obino MER; Micelli E; Malacarne E; Vacca C; Papini F; Cela V
Gynecol Endocrinol; 2020 Sep; 36(9):755-759. PubMed ID: 32157927
[TBL] [Abstract][Full Text] [Related]
3. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
Fruzzetti F; Capozzi A; Canu A; Lello S
Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488
[TBL] [Abstract][Full Text] [Related]
4. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study.
La Marca A; Grisendi V; Dondi G; Sighinolfi G; Cianci A
Gynecol Endocrinol; 2015 Jan; 31(1):52-6. PubMed ID: 25268566
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
Cappelli V; Di Sabatino A; Musacchio MC; De Leo V
Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
[TBL] [Abstract][Full Text] [Related]
6. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
[TBL] [Abstract][Full Text] [Related]
7. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Nordio M; Proietti E
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.
Laganà AS; Barbaro L; Pizzo A
Arch Gynecol Obstet; 2015 May; 291(5):1181-6. PubMed ID: 25416201
[TBL] [Abstract][Full Text] [Related]
9. Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study.
Rago R; Marcucci I; Leto G; Caponecchia L; Salacone P; Bonanni P; Fiori C; Sorrenti G; Sebastianelli A
J Biol Regul Homeost Agents; 2015; 29(4):913-23. PubMed ID: 26753656
[TBL] [Abstract][Full Text] [Related]
10. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A; Laganà AS; Barbaro L
Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
[TBL] [Abstract][Full Text] [Related]
11. Familial diabetes predisposes PCOS patients to insulin resistance (IR), reproductive impairment and hepatic dysfunction: effects of d-chiro inositol (DCI) and alpha lipoic acid (ALA) administration on hepatic insulin extraction (HIE) index.
Genazzani AD; Battipaglia C; Petrillo T; Piacquadio N; Ambrosetti F; Arnesano M; Semprini E; Sponzilli A; Tomatis V; Simoncini T
Gynecol Endocrinol; 2022 Aug; 38(8):681-688. PubMed ID: 35748584
[No Abstract] [Full Text] [Related]
12. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
Minozzi M; Nordio M; Pajalich R
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):537-40. PubMed ID: 23467955
[TBL] [Abstract][Full Text] [Related]
13. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
Dinicola S; Chiu TT; Unfer V; Carlomagno G; Bizzarri M
J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
[TBL] [Abstract][Full Text] [Related]
14. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
Monastra G; Unfer V; Harrath AH; Bizzarri M
Gynecol Endocrinol; 2017 Jan; 33(1):1-9. PubMed ID: 27898267
[TBL] [Abstract][Full Text] [Related]
15. HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA).
Cirillo F; Catellani C; Lazzeroni P; Sartori C; Tridenti G; Vezzani C; Fulghesu AM; Madeddu E; Amarri S; Street ME
Gynecol Endocrinol; 2020 Jul; 36(7):588-593. PubMed ID: 32054355
[TBL] [Abstract][Full Text] [Related]
16. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Unfer V; Porcaro G
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
[TBL] [Abstract][Full Text] [Related]
17. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
De Cicco S; Immediata V; Romualdi D; Policola C; Tropea A; Di Florio C; Tagliaferri V; Scarinci E; Della Casa S; Lanzone A; Apa R
Gynecol Endocrinol; 2017 Sep; 33(9):698-701. PubMed ID: 28434274
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
Fruzzetti F; Perini D; Russo M; Bucci F; Gadducci A
Gynecol Endocrinol; 2017 Jan; 33(1):39-42. PubMed ID: 27808588
[TBL] [Abstract][Full Text] [Related]
19. Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.
Paul C; Laganà AS; Maniglio P; Triolo O; Brady DM
Gynecol Endocrinol; 2016 Jun; 32(6):431-8. PubMed ID: 26927948
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
Zacchè MM; Caputo L; Filippis S; Zacchè G; Dindelli M; Ferrari A
Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
